Shares of medical equipment maker Integra plunge amid flooding at facility

Shares of Integra LifeSciences, a small-cap maker of equipment used in brain surgery and technologies for treating complex wounds, plunged 21% on Friday. The company said that flooding in July destroyed some inventory and equipment at its manufacturing facility in Ohio, leading to weak quarterly results and the management lowering its full-year guidance.

Integra fell 21% on the Nasdaq on Friday to $12.70 per share, its lowest close since early May. According to the company’s preliminary third-quarter results, revenue increased about 2% year over year to $410-412 million. Adjusted earnings per diluted share for the reporting period came in at approximately $0.55-0.59, versus a loss of $0.07 per share in the same period of 2025.

The third-quarter results were affected by damage to Integra’s facility caused by flooding in Cincinnati, Ohio, in July, CEO Stuart Essig explained. More than six inches of rain fell in the city in one hour, causing a floodgate on the river to fail and flooding a number of roads, homes, and businesses, the University of Cincinnati noted. The flooding disrupted the Integra facility’s operations, destroying some equipment, inventory, and other assets and causing supply interruptions. As a result, the small company lost approximately $7 million in third-quarter revenue and expects to lose another $15-20 million in the fourth quarter.

Integra lowered its full-year 2026 revenue guidance. The previous range was $1.65-1.70 billion, implying growth of 1.0-3.5%. Under the updated outlook, the company expects revenue of $1.63-1.65 billion, roughly in line with last year. It also said EPS for 2026 would come in at $2.30-2.40, versus its previous forecast of $2.40-2.50. In 2025, the company posted a loss of $6.74 per share. The company expects the facility to return to full production in the second quarter of 2027.

Despite the selloff, Integra shares remain in the black this year, now up 2% since January. Wall Street is generally cautious on the stock: it has seven “hold” ratings, three “buy” calls, and two “sell” recommendations. The average target price is $18.90 per share, implying 49% upside from the last close.